GLP-1 in Canada 2026: Approvals, CAD Prices, Provincial Coverage, and Telehealth

Canada is in a strange moment for GLP-1 access. Every major drug in the class is now approved here, but most provincial plans only pay for diabetes. The 2023–2024 Ozempic shortage is over. Zepbound finally launched in 2025. And in April 2026, Canada became the first G7 country to approve a generic semaglutide — which is already pulling list prices down. This guide pulls all of that into one place: what's approved, what it costs in Canadian dollars, what your province actually covers, and how to legitimately get a prescription through a Canadian telehealth service.

Direct answer: As of May 2026, Canadians have access to Ozempic (semaglutide, diabetes), Wegovy (semaglutide, obesity), Rybelsus (oral semaglutide, diabetes), Mounjaro (tirzepatide, diabetes), Zepbound (tirzepatide, obesity, approved May 13 2025, in pharmacies July 2025), and Saxenda (liraglutide, obesity). Self-pay pricing runs roughly $230–$280 CAD/month for Ozempic, $400–$570 CAD/month for Wegovy, $300–$540 CAD/month for Mounjaro/Zepbound, and $350–$450 CAD/month for Saxenda. Provincial plans (ODB in Ontario, RAMQ in Quebec, BC PharmaCare, Alberta Blue Cross, etc.) only cover GLP-1s for type 2 diabetes, almost never for weight loss. Private insurance covers obesity inconsistently — roughly 31% of Canadian employer plans include some GLP-1 weight-loss coverage. The Ozempic shortage that defined 2023–2024 is resolved as of January 2025. Buying from US pharmacies and importing into Canada is not legal under the Food and Drugs Act for personal use without proper authorization. The cheaper path is a Canadian telehealth provider (Felix, Maple, Pocketpills, Walk In) plus, increasingly, generic semaglutide (Dr. Reddy's "Obeda" approved April 29, 2026; Apotex second-to-market).

What's Approved in Canada (May 2026)

A few things worth flagging:

• Canada lagged the US on Wegovy. Health Canada approved it in 2021 but Novo Nordisk only launched it commercially here in May 2024 because of global shortage allocation. That's also why the 2023–2024 Ozempic shortage was so severe in Canada — Novo was preserving semaglutide capacity for the more recently launched US Wegovy market.
• Zepbound was approved two years after the US (US approval was November 2023). Canadian Zepbound is sold only as the multi-dose KwikPen — no vial-and-syringe option.
• Rybelsus (the oral semaglutide pill) only landed in Canada in January 2026, even though it's been available in the US since 2019.
• Generic semaglutide is currently approved only for diabetes, not for weight loss — Wegovy's separate use patent extends beyond the underlying compound patent.

List Prices in Canadian Dollars

Self-pay numbers from across major Canadian retail pharmacies, May 2026:

Add roughly $10–$15 in dispensing fees per fill and $5–$15 in delivery if you order online.

For context: Wegovy at ~$400 CAD/month is roughly half what self-pay Americans paid before Novo's NovoCare Pharmacy direct channel dropped US list price to $499 USD. Zepbound in Canada is also markedly cheaper than the US cash list price, before US savings programs.

Public Coverage by Province

The pattern is consistent across the country: public plans pay for GLP-1s in diabetes, not in obesity. Below is what each major plan covers as of May 2026.

Ontario — ODB (Ontario Drug Benefit)

Covers Ozempic, Rybelsus, Mounjaro, and (post-generic) Obeda for type 2 diabetes in patients who have not reached target A1c on metformin and at least one other oral agent. Wegovy, Zepbound, and Saxenda are not covered for weight management. Seniors over 65 and ODSP recipients are the largest beneficiaries.

Quebec — RAMQ

Public prescription drug insurance covers Ozempic and Rybelsus for diabetes; co-payment is income-based, up to roughly 35% of the cost. Wegovy and Saxenda for obesity are not on the formulary. Quebec also has unique structural coverage: residents must be enrolled in either RAMQ's public plan or a private plan — there is no opt-out.

British Columbia — PharmaCare

Covers Ozempic for type 2 diabetes when first-line agents (metformin) haven't achieved adequate glycemic control. BC PharmaCare also published a public Drug Information Sheet for semaglutide explicitly to clarify it is not a weight-loss benefit. Zepbound, Wegovy, Saxenda are self-pay or private-insurance.

Alberta — Alberta Blue Cross / Alberta Health

Covers GLP-1s for diabetes via Alberta Health under the Step Therapy framework — patients usually need documented failure of metformin first. Special authorization required. Weight-loss indications are not covered.

Atlantic Canada (NS, NB, PEI, NL)

Most limited. Nova Scotia covers GLP-1s under its diabetes assistance and Family Pharmacare programs with prior authorization for diabetes only. New Brunswick and Newfoundland generally require special authorization for diabetes coverage and offer essentially no obesity coverage. PEI similarly restricts to diabetes.

Federal plans (NIHB, PSHCP, Veterans Affairs)

The Non-Insured Health Benefits program for First Nations and Inuit covers Ozempic and Rybelsus for diabetes after step therapy. The Public Service Health Care Plan and Veterans Affairs follow similar rules — diabetes yes, obesity case-by-case with prior authorization.

The blunt summary: if you're using a GLP-1 for weight loss in Canada, you should plan on paying out of pocket or through private insurance.

Private Insurance Coverage

About 31% of Canadian employer-sponsored plans include some GLP-1 coverage, but of those, roughly 56% restrict it to diabetes only. That leaves a small slice — maybe 14% of Canadian workers — with employer-side coverage that may pay for Wegovy or Zepbound after prior authorization.

What you'll see by insurer:

• Manulife — May cover Wegovy under select plans; Ozempic typically diabetes-only.
• Sun Life — Optional weight-management rider; usually requires BMI ≥30 (or ≥27 with comorbidity), prior authorization, and step therapy.
• Canada Life — Customizable; the company publishes a specific Prior Authorization form for Ozempic, Rybelsus, and other GLP-1s requiring A1c history and prior agent failure.
• Blue Cross (Pacific Blue Cross, Medavie, etc.) — Coverage varies by employer; weight-loss often an add-on rider.
• GreenShield Canada — May cover with strict criteria; prior authorization required.

Even with coverage, expect coinsurance of 10–50% and an annual or lifetime cap. The pattern with new GLP-1 entrants: insurers cover the diabetes indication first, then add the weight-management indication 12–24 months later as utilization data accumulates.

Shortage Status

Canada's GLP-1 supply situation has fully stabilized as of early 2025. The key dates:

• August 2023 – February 2024 — Severe Ozempic shortage. Health Canada issued a public advisory recommending against most new Ozempic prescriptions during the worst stretch.
• March 2023 — British Columbia restricted Ozempic sales to non-Canadians after large US-based volumes were filled at BC pharmacies. The restriction is still in force in practice.
• December 2023 — Health Canada said the shortage would persist into 2024; Mounjaro and Trulicity also intermittently short.
• February 2024 — Supply resumed normalizing.
• January 27, 2025 — Health Canada formally noted supply of Ozempic and other GLP-1 receptor agonists has stabilized.
• 2025–2026 — No active national shortage, though localized stock-outs of specific dose pens still happen and Wegovy initiation doses (0.25 mg, 0.5 mg) periodically run thin at individual pharmacies.

Generic semaglutide entering the market in 2026 will further ease pressure on the supply chain.

Buying From the US — Don't

A small but persistent group of Canadians, often near the Quebec–Vermont or BC–Washington borders, ask whether they can fill cheaper US prescriptions and bring them home. Short answer: importing prescription drugs into Canada for personal use without proper authorization is not permitted under the Food and Drugs Act.

The specifics:

• Health Canada and CBSA enforce the rule jointly. They can seize, destroy, or order removal of any health product believed to contravene the Act, whether it comes by mail, courier, or in your luggage.
• There is a narrow personal-use exemption for a 90-day supply of a drug you were already taking before arrival, in original packaging, with documentation — but it does not cover routinely buying a cheaper US supply to bypass Canadian pricing.
• Online "Canadian pharmacy" sellers based offshore that ship internationally are a separate enforcement category and not the same as licensed Canadian retail pharmacies.

In the other direction, BC restricted Ozempic exports to non-Canadians in 2023 partly because so many US patients were having Canadian pharmacies fill their prescriptions during the US shortage.

The point: the legal path for a Canadian is a Canadian prescription filled at a Canadian pharmacy.

Telehealth Options Inside Canada

Several Canadian platforms offer end-to-end online assessment and prescription for GLP-1s. None of them can advertise drug prices publicly — that's illegal in Canada for prescription drugs — so you only see numbers after starting the assessment.

A few specifics worth highlighting:

• Felix's pricing reset. As of mid-May 2026, Felix announced a semaglutide price reduction of up to 65% taking effect May 29, 2026, anchored by the new generic. The company's own data showed only 5% of Canadians with overweight or obesity would consider GLP-1 treatment at $400/month, versus 28% at $100/month — a strong signal of where the market is heading.
• Insurance handling. Felix submits private insurance claims directly. About 40% of Felix patients see partial or full coverage for the first prescription.
• Initial assessment is not insured. Almost all Canadian telehealth platforms charge a private fee for the GLP-1 program assessment, which is rarely reimbursed by either provincial or private plans.

Canada vs the US — How the Numbers Compare

Headline: branded Canadian GLP-1s are roughly the same to somewhat cheaper than US cash equivalents, but Canadian patients without coverage face a steeper relative burden because compounded semaglutide doesn't exist as a legal option here. The generic launch starting late 2026 is the lever that may finally pull Canadian obesity GLP-1 costs into the $100–$150 CAD/month range.

What People Get Wrong About GLP-1 in Canada

• "Ozempic is covered by OHIP." Only for diabetes that has failed first-line therapy. Off-label weight loss is not.
• "I can order Wegovy cheaper from the US." Importing GLP-1s for personal use without authorization isn't permitted. CBSA does seize shipments.
• "There's still an Ozempic shortage." The national shortage ended in early 2024 and Health Canada formally confirmed normal supply in January 2025.
• "Generic Wegovy will be cheap next year." The April 2026 generic (Obeda) is approved for diabetes only — Wegovy's weight-management indication has its own patent timeline.
• "My benefits cover Wegovy because they cover Ozempic." Most insurers treat the obesity indication separately and require a different prior authorization.
• "Felix sells GLP-1s like a US telehealth company." Felix prescribes and routes to a partner pharmacy — they cannot advertise drug prices, and you'll see numbers only after starting an assessment.
• "Zepbound has been in Canada the whole time." No — Zepbound was approved May 13, 2025 and hit pharmacies in July 2025, about 18 months after the US.
• "I can get reimbursed by my province if my doctor writes a letter." Off-label weight-loss prescriptions are essentially never reimbursed by public plans regardless of letters.

Frequently Asked Questions

Is Wegovy available in Canada? Yes. Health Canada approved Wegovy in 2021, but Novo Nordisk only launched it commercially in Canada in May 2024 due to global supply allocation.

How much does Wegovy cost in Canada without insurance? Roughly $400–$570 CAD per month at retail pharmacies, with bulk purchases of three pens dropping the per-pen price to around $399.

Does OHIP cover Ozempic? Yes, but only for type 2 diabetes after failure on metformin and at least one other oral agent. OHIP does not cover Ozempic or Wegovy for weight loss.

Is Zepbound approved in Canada? Yes. Health Canada approved Zepbound on May 13, 2025, and it became available at Canadian pharmacies on July 9, 2025. It is sold only as a multi-dose KwikPen.

Can I import GLP-1 medications from the US into Canada? Not for routine personal use without proper authorization. Health Canada and CBSA can seize shipments. A narrow exemption exists for a 90-day supply of a drug you were already taking, with documentation.

Is there still an Ozempic shortage in Canada? No. The 2023–2024 shortage was resolved by early 2024, and Health Canada formally confirmed stable supply in January 2025. Localized stock-outs of specific dose pens can still occur.

Does generic Ozempic exist in Canada? Yes — Dr. Reddy's Laboratories received Health Canada approval on April 29, 2026 for generic semaglutide (brand name Obeda) for type 2 diabetes, making Canada the first G7 country to approve a semaglutide generic. Apotex followed in May 2026.

Will generic semaglutide be available for weight loss? Not initially. The current Canadian generics are approved only for diabetes; Wegovy's weight-management patent has separate exclusivity.

Is Felix or Maple better for GLP-1 in Canada? Felix is bigger and specializes in weight-loss-focused care including dose escalation support. Maple is a general telehealth platform with a Weight Medication Assessment add-on. For complex diabetes, an endocrinology specialist (e.g. LMC) is usually a better fit.

Does private insurance in Canada cover Wegovy? Sometimes. About 31% of Canadian employer plans include GLP-1 coverage, but roughly 56% of those plans restrict it to diabetes. Wegovy coverage usually requires prior authorization and BMI documentation.

Why is Wegovy more expensive in Canada than Zepbound? Pricing reflects Novo Nordisk's launch strategy and lack of a Wegovy patient-support program comparable to Eli Lilly's Myzepbound PSP. Zepbound's PSP drops list price by $40–$171 CAD/month.

Last reviewed: May 13, 2026

Sources

• Can you get GLP-1 drugs in Canada? — Canadian Medical Association
• Canada becomes the first G7 country to approve a generic version of semaglutide — Health Canada
• Canada approves second generic semaglutide — Health Canada
• Health Canada approves 1st generic version of Ozempic — CBC News
• With Canada approving 1st generic semaglutide, how will costs compare? — Global News
• Supply of Ozempic and other GLP-1 receptor agonists: Notice — Health Canada
• Bringing health products into Canada for personal use (GUI-0116) — Health Canada
• Zepbound (tirzepatide) Product Monograph — Lilly Canada
• Zepbound Now Available in Canada: Price, Dosages — GLP1Prices.ca
• How Much Does Wegovy Cost in Canada? — Maple
• Weight Loss Drugs Covered by Group Insurance in Canada — PolicyAdvisor
• Felix Health to Lower Semaglutide Pricing by Up to 65% — GlobeNewswire
• Felix Weight Loss Program Pricing — Felix Health
• Zepbound Canada: Cost, Dosing — Walk In Virtual Doctors
• B.C. PharmaCare Drug Information Sheet for semaglutide (Wegovy) — Government of British Columbia
• Drug Prior Authorization Form: Ozempic, Rybelsus, and other GLP-1s — Canada Life